Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.410
+0.010 (0.42%)
At close: Jun 23, 2026, 4:00 PM EDT
2.420
+0.010 (0.41%)
After-hours: Jun 23, 2026, 4:10 PM EDT
Acumen Pharmaceuticals Employees
Acumen Pharmaceuticals had 61 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
61
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,856,984
Market Cap
174.07M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 61 | 0 | - | 60 | 1 |
| Dec 31, 2024 | 61 | 9 | 17.31% | 61 | 0 |
| Dec 31, 2023 | 52 | 12 | 30.00% | 51 | 1 |
| Dec 31, 2022 | 40 | 23 | 135.29% | 39 | 1 |
| Dec 31, 2021 | 17 | 10 | 142.86% | 14 | 3 |
| Mar 31, 2021 | 7 | - | - | 7 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Innate Pharma | 164 |
| LENZ Therapeutics | 152 |
| MediWound | 121 |
| Precision BioSciences | 66 |
| OnKure Therapeutics | 45 |
| Milestone Pharmaceuticals | 38 |
| NovaBridge Biosciences | 30 |
ABOS News
- 6 days ago - JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire
- 7 days ago - Acumen nominates two development candidates in EBD program - TheFly
- 7 days ago - Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer's Disease - GlobeNewsWire
- 5 weeks ago - Acumen Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Acumen Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 6 weeks ago - Acumen Pharmaceuticals Earnings release: Q1 2026 - Filings
- 6 weeks ago - Acumen Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire